Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$71.71 USD
+0.19 (0.27%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $71.76 +0.05 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -239.24 | -187.13 | -130.40 | -102.90 | -68.35 |
Depreciation/Amortization & Depletion | 9.41 | 7.05 | 2.23 | 0.86 | 0.69 |
Net Change from Assets/Liabilities | -28.24 | 22.55 | -0.86 | 0.42 | 15.17 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 112.99 | 41.02 | 20.80 | 23.16 | 6.12 |
Net Cash From Operating Activities | -145.08 | -116.51 | -108.23 | -78.46 | -46.38 |
Property & Equipment | -0.58 | -0.70 | -0.31 | -0.05 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -53.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.58 | -53.70 | -0.31 | -0.05 | -0.02 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 271.17 | 243.04 | 11.61 | 15.18 | 239.63 |
Issuance (Repayment) of Debt | 85.00 | 45.00 | 0.00 | 28.34 | 12.76 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -25.16 | -3.46 | -0.49 | -1.10 | 0.00 |
Net Cash from Financing Activities | 331.01 | 284.58 | 11.13 | 42.41 | 252.39 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 185.35 | 114.37 | -97.40 | -36.09 | 206.00 |
Cash at Beginning of Period | 200.84 | 86.47 | 183.88 | 219.97 | 13.97 |
Cash at End of Period | 386.19 | 200.84 | 86.47 | 183.88 | 219.97 |
Diluted Net EPS | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 |
Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -239.24 | -140.59 | -78.39 | -11.22 |
Depreciation/Amortization & Depletion | NA | 9.41 | 7.21 | 5.62 | 2.56 |
Net Change from Assets/Liabilities | NA | -28.24 | -31.88 | -23.15 | -9.94 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 112.99 | 50.53 | 34.76 | 12.78 |
Net Cash From Operating Activities | NA | -145.08 | -114.72 | -61.17 | -5.82 |
Property & Equipment | NA | -0.58 | -0.58 | -0.20 | -0.07 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.58 | -0.58 | -0.20 | -0.07 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 271.17 | 270.02 | 231.96 | 0.39 |
Issuance (Repayment) of Debt | NA | 85.00 | 85.00 | 85.00 | 55.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -25.16 | -24.01 | -19.31 | -3.82 |
Net Cash from Financing Activities | NA | 331.01 | 331.02 | 297.65 | 51.57 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 185.35 | 215.72 | 236.27 | 45.67 |
Cash at Beginning of Period | NA | 200.84 | 200.84 | 200.84 | 200.84 |
Cash at End of Period | NA | 386.19 | 416.56 | 437.11 | 246.52 |
Diluted Net EPS | NA | -2.15 | -1.32 | -1.54 | -0.26 |